X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Novo Nordisk has obtained all exclusive rights to develop and commercialize EraCal’s oral small molecule asset to control appetite and body weight with an eye toward treating obesity.
Lead Product(s): Undisclosed
Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novo Nordisk
Deal Size: $255.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 23, 2024
Details:
Under the joint research plan, EraCal and Novo Nordisk will investigate novel molecules for their potential as anti-obesity pharmacotherapy. This will be done in zebrafish larvae, an emerging vertebrate drug discovery platform.
Lead Product(s): Undisclosed
Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Peptide
Partner/Sponsor/Collaborator: Novo Nordisk
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 17, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
